Plasma Concentrations of Isoniazid and Rifampin Are Decreased in Adult Pulmonary Tuberculosis Patients with Diabetes Mellitus

被引：70

作者：

Babalik, Aylin ^{[1
]}

Ulus, Ismail Hakki ^{[2
]}

Bakirci, Nadi ^{[3
]}

Kuyucu, Tulin ^{[1
]}

Arpag, Huseyin ^{[1
]}

Dagyildizi, Lale ^{[1
]}

Capaner, Esen ^{[4
]}

机构：

[1] Sureyyapasa Chest Dis & Thorac Surg Training & Re, Istanbul, Turkey

[2] Acibadem Univ, Dept Pharmacol, Sch Med, Istanbul, Turkey

[3] Acibadem Univ, Dept Publ Hlth, Sch Med, Istanbul, Turkey

[4] Kaan Med Toxicol Lab, Istanbul, Turkey

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2013年 / 57卷 / 11期

关键词：

EARLY BACTERICIDAL ACTIVITY; PHARMACOKINETICS; MANIFESTATIONS; IMPACT; DRUGS;

D O I：

10.1128/AAC.01345-13

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Plasma isoniazid and rifampin concentrations, but not pyrazinamide and ethambutol concentrations, were decreased by about 50% (P < 0.05) in diabetic pulmonary tuberculosis patients. The prevalences of subnormal plasma isoniazid, rifampin, pyrazinamide, and ethambutol concentrations were 49% or 100% (P < 0.01), 66% or 100% (P < 0.05), 30% or 50% (P = 0.198), and 32% or 21% (P = 0.742) in nondiabetic or diabetic tuberculosis patients, respectively. These data show that plasma concentrations of isoniazid and rifampin were greatly reduced in diabetic tuberculosis patients.

引用

页码：5740 / 5742

页数：3

共 21 条

[1]

Alisjahbana B, 2006, INT J TUBERC LUNG D, V10, P696

[2] The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis [J].

Alisjahbana, Bachti ;

Sahiratmadja, Edhyana ;

Nelwan, Erni J. ;

Purwa, Anugrah Maya ;

Ahmad, Yana ;

Ottenhoff, Tom H. M. ;

Nelwan, Ronald H. H. ;

Parwati, Ida ;

van der Meer, Jos W. M. ;

van Crevel, Reinout .

CLINICAL INFECTIOUS DISEASES, 2007, 45 (04) :428-435

[3] Therapeutic drug monitoring in the treatment of active tuberculosis [J].

Babalik, Aylin ;

Mannix, Sharyn ;

Francis, Denis ;

Menzies, Dick .

CANADIAN RESPIRATORY JOURNAL, 2011, 18 (04) :225-229

[4] Effect of Type 2 Diabetes Mellitus on the Clinical Severity and Treatment Outcome in Patients With Pulmonary Tuberculosis: A Potential Role in the Emergence of Multidrug-resistance [J].

Chang, Jenn-Tyang ;

Dou, Horng-Yunn ;

Yen, Chia-Liang ;

Wu, Ying-Hsun ;

Huang, Ruay-Ming ;

Lin, Huey-Juan ;

Su, Ih-Jen ;

Shieh, Chi-Chang .

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2011, 110 (06) :372-381

[5] Determination of ethambutol in plasma by high-performance liquid chromatography after pre-column derivatization [J].

Chenevier, P ;

Massias, L ;

Gueylard, D ;

Farinotti, R .

JOURNAL OF CHROMATOGRAPHY B, 1998, 708 (1-2) :310-315

[6] Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study [J].

Dobler, Claudia Caroline ;

Flack, Jeffrey Ronald ;

Marks, Guy Barrington .

BMJ OPEN, 2012, 2 (01)

[7] The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis [J].

Donald, PR ;

Sirgel, FA ;

Botha, FJ ;

Seifart, HI ;

Parkin, DP ;

Vandenplas, ML ;

vandeWal, BW ;

Maritz, JS ;

Mitchison, DA .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 156 (03) :895-900

[8]

Dostalek M, 2012, CLIN PHARMACOKINET, V51, P481, DOI 10.2165/11631900-000000000-00000

[9] Type 2 diabetes and multidrug-resistant tuberculosis [J].

Fisher-Hoch, Susan P. ;

Whitney, Erin ;

Mccormick, Joseph B. ;

Crespo, Gonzalo ;

Smith, Brian ;

Rahbar, Mohammad H. ;

Restrepo, Blanca I. .

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2008, 40 (11-12) :888-893

[10] Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA [J].

Heysell, Scott K. ;

Moore, Jane L. ;

Keller, Suzanne J. ;

Houpt, Eric R. .

EMERGING INFECTIOUS DISEASES, 2010, 16 (10) :1546-1553

← 1 2 3 →